Biosimilars
What are biosimilars? The Pharmacy Times® Biosimilars resource center keeps those in the space up to date with the latest clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
![[[thumbnail_alt_text]]](https://specialtypharmacytimes.s3.amazonaws.com/v1_media/_thumbs/AdobeStock_174984032.jpeg)
Biosimilars adalimumab and etanercept showed equivalent safety and efficacy to reference products in patients with rheumatoid arthritis.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/v1_media/SafeImages/LaptopAdobeStock_81964367.jpg)
Several hurdles remain for biosimilars to flourish in the US market.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/v1_media/SafeImages/Webdam%20Assets/Beaker%20science.jpg)
Presenters delved into the topic of biological drugs and gene therapy during the recent International Pharmaceutical Federation (FIP) World Congress in Glasgow Scotland.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2019-09-13_Screen_Shot_2019-09-13_at_11.37.03_AM.png)
Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses biosimilars and the potential impact on patient care.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/v1_media/SafeImages/Webdam%20Assets/FDA3-644px.jpg)
Based on 2017 FDA research, the delayed market launch of nine biosimilars represented $4.5 billion in potential savings.
![[[thumbnail_alt_text]]](https://specialtypharmacytimes.s3.amazonaws.com/v1_media/_thumbs/v1_media/_upload_image/_thumbnails/Prescription drug - money inside pill capsule.jpg)
With drugs that achieve similar clinical outcomes, it will ultimately come down to financial differentiation that can determine which drugs lead the market.
![[[thumbnail_alt_text]]](https://specialtypharmacytimes.s3.amazonaws.com/v1_media/_thumbs/v1_media/_upload_image/_thumbnails/Biosimilars web.png)
Biosimilars are a potential solution to the ever-growing problem of high specialty drug costs.
![[[thumbnail_alt_text]]](https://specialtypharmacytimes.s3.amazonaws.com/v1_media/_thumbs/v1_media/_upload_image/_thumbnails/Week in Review-2.png)
Top news of the week from Specialty Pharmacy Times.
![[[thumbnail_alt_text]]](https://specialtypharmacytimes.s3.amazonaws.com/v1_media/_thumbs/v1_media/_upload_image/_thumbnails/Prescription drugs - white and red pills.jpg)
New policies that aim to help generic drug makers move their products through the development and approval processes more efficiently have been announced by FDA Commissioner Scott Gottlieb, MD.
A new 5-part video series released by the FDA is part of a larger education and outreach effort about biosimilars and interchangeable products.
Top news of the week from Specialty Pharmacy Times.
Retacrit gains FDA approval as a biosimilar to Epogen/Procrit for the treatment of anemia caused by chronic kidney disease, chemotherapy, or in patients with HIV.